Friday, 16 October 2026European Markets

MERLIN PROPERTIES, INTERVEST OFF-WARE, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(VIANEWS) - MERLIN PROPERTIES (MRL.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Real Estate sector.

Financial Asset Price Forward Dividend Yield Return on Equity
MERLIN PROPERTIES (MRL.LS) €8.06 15% 9.59%
INTERVEST OFF-WARE (INTO.BR) €17.42 8.74% 8.44%
IMMO MOURY (IMMOU.BR) €39.20 4.48% 13.16%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. MERLIN PROPERTIES (MRL.LS)

15% Forward Dividend Yield and 9.59% Return On Equity

MERLIN Properties SOCIMI, SA, one of the main real estate companies listed on the Spanish Stock Exchange (IBEX-35), has as its main activity the acquisition and management of tertiary real estate assets in the Iberian Peninsula. The Company is a public limited company incorporated as a SOCIMI. The main activity of the Company is the acquisition, active management, operation and selective rotation of quality commercial real estate assets in the investment segment “Core” and “Core Plus”, mainly in Spain and, to a lesser extent, in Portugal. The Company focuses on the office, retail and logistics market.

Earnings Per Share

As for profitability, MERLIN PROPERTIES has a trailing twelve months EPS of €0.09.

PE Ratio

MERLIN PROPERTIES has a trailing twelve months price to earnings ratio of 67.17. Meaning, the purchaser of the share is investing €67.17 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.59%.

More news about MERLIN PROPERTIES.

2. INTERVEST OFF-WARE (INTO.BR)

8.74% Forward Dividend Yield and 8.44% Return On Equity

Intervest Offices & Warehouses nv, (hereinafter Intervest), is a public regulated real estate company (RREC) founded in 1996 of which the shares are listed on Euronext Brussels (INTO) as from 1999. Intervest invests in high-quality Belgian office buildings and logistics properties that are leased to first-class tenants. The properties in which Intervest invests, consist primarily of up-to-date buildings that are strategically located in the city centre and outside municipal centres. The offices of the real estate portfolio are situated in and around centre cities with a large student population such as Antwerp, Mechelen, Brussels and Leuven; the logistics properties are located on the Antwerp - Brussels - Nivelles, Antwerp - Limburg - Liège, and Antwerp - Ghent - Lille axes and concentrated in the Netherlands on the Moerdijk - ‘s-Hertogenbosch - Nijmegen, Rotterdam - Gorinchem - Nijmegen and Bergen-op-zoom - Eindhoven - Venlo axes. Intervest distinguishes itself when leasing space by offering more than square metres only. The company goes beyond real estate by offering ‘turn-key solutions' (a tailor-made global solution for and with the customer), extensive services provisioning, co-working and serviced offices.

Earnings Per Share

As for profitability, INTERVEST OFF-WARE has a trailing twelve months EPS of €1.94.

PE Ratio

INTERVEST OFF-WARE has a trailing twelve months price to earnings ratio of 8.98. Meaning, the purchaser of the share is investing €8.98 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.44%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 72.03M for the twelve trailing months.

Volatility

INTERVEST OFF-WARE's last week, last month's, and last quarter's current intraday variation average was a positive 1.74%, a negative 0.42%, and a positive 1.18%.

INTERVEST OFF-WARE's highest amplitude of average volatility was 1.74% (last week), 1.24% (last month), and 1.18% (last quarter).

Moving Average

INTERVEST OFF-WARE's value is way below its 50-day moving average of €19.61 and way under its 200-day moving average of €21.98.

Yearly Top and Bottom Value

INTERVEST OFF-WARE's stock is valued at €17.42 at 17:30 EST, way below its 52-week high of €29.70 and above its 52-week low of €17.16.

More news about INTERVEST OFF-WARE.

3. IMMO MOURY (IMMOU.BR)

4.48% Forward Dividend Yield and 13.16% Return On Equity

Immo Moury SCA is a real estate investment trust. Immo Moury SCA is based in Belgium.

Earnings Per Share

As for profitability, IMMO MOURY has a trailing twelve months EPS of €11.5.

PE Ratio

IMMO MOURY has a trailing twelve months price to earnings ratio of 3.41. Meaning, the purchaser of the share is investing €3.41 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.16%.

Moving Average

IMMO MOURY's worth is under its 50-day moving average of €40.20 and under its 200-day moving average of €41.59.

Revenue Growth

Year-on-year quarterly revenue growth grew by 9.5%, now sitting on 2.29M for the twelve trailing months.

More news about IMMO MOURY.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com